PTC THERAPEUTICS, INC. 4

CEO Matthew B. Klein sold 10,292 shares of PTC Therapeutics, Inc. common stock at $68.57 per share in an automatic sell-to-cover transaction related to RSU vesting, leaving him with 383,868 shares owned.

On August 4, 2026, PTC Therapeutics, Inc. CEO Matthew B. Klein automatically sold 10,292 shares of common stock at an average price of $68.57 per share, totaling approximately $706,000, pursuant to an irrevocable sell-to-cover election to satisfy tax withholding obligations arising from the vesting of 25,000 RSUs from an August 1, 2025 grant of 75,000 RSUs. Following this tax-related sale, Klein beneficially owns 383,868 shares of PTC Therapeutics common stock, which includes 162 shares acquired under the company’s employee stock purchase plan for the period ended June 30, 2026; the retained stake is valued at roughly $26.35 million based on the reported sale price as a proxy for current market value.

Filing Facts

CIK

1070081

Ticker

PTCT

Form

4

Source Type

fda

Accession

0001808968-26-000017

Alert Tier

6